FRIMIG

This brand name is authorized in Lithuania, Poland

Active ingredients

The drug FRIMIG contains one active pharmaceutical ingredient (API):

1 Sumatriptan
UNII J8BDZ68989 - SUMATRIPTAN SUCCINATE

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction.

Read about Sumatriptan

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N02CC01 Sumatriptan N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CC Selective serotonin (5HT1) agonists
Discover more medicines within N02CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1086515
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100171448, 100204410, 100349975, 100371443, 100399915, 100406561, 100407649, 100422962

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈